Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

By Swaisland H.  

Clinical Pharmacokinetics, Vol. 40, Iss. 4, 2001-01 ,pp. : 297-306

Adis International

Access to resources Recommend Favorite

A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

By MacKenzie Mary   Hirte Holger   Glenwood Goss   Jean Maroun   Goel Rakesh   Major Pierre   Miller Jr. Wilson   Panasci Lawrence   Lorimer Ian   Batist Gerald   Matthews Sarah   Douglas Lynn   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 165-170

Springer Publishing Company

Access to resources Recommend Favorite

Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer: State of the Art

By Diasio Robert B.   Fourie Jeanne  

Drugs, Vol. 66, Iss. 11, 2006-01 ,pp. : 1441-1463

Adis International

Access to resources Recommend Favorite

Anti-epidermal growth factor receptor drugs in cancer therapy

By Tortora Giampaolo   Ciardiello Fortunato  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 6, 2002-06 ,pp. : 755-768

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor

By  

Current Drug Targets, Vol. 6, Iss. 3, 2005-05 ,pp. : 275-287

Bentham Science Publishers

Access to resources Recommend Favorite